Geode Capital Management LLC Lowers Stake in Haemonetics Corporation $HAE

Geode Capital Management LLC lowered its stake in shares of Haemonetics Corporation (NYSE:HAE) by 0.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,194,551 shares of the medical instruments supplier’s stock after selling 8,829 shares during the quarter. Geode Capital Management LLC’s holdings in Haemonetics were worth $95,758,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Hantz Financial Services Inc. raised its position in shares of Haemonetics by 52.5% during the 4th quarter. Hantz Financial Services Inc. now owns 1,714 shares of the medical instruments supplier’s stock valued at $137,000 after buying an additional 590 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Haemonetics by 366.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,709 shares of the medical instruments supplier’s stock valued at $137,000 after purchasing an additional 1,343 shares during the last quarter. Legato Capital Management LLC bought a new position in shares of Haemonetics during the 4th quarter valued at $1,057,000. Global Retirement Partners LLC bought a new position in shares of Haemonetics during the 4th quarter valued at $270,000. Finally, Leonteq Securities AG bought a new position in shares of Haemonetics during the 4th quarter valued at $30,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Barrington Research reduced their target price on shares of Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a report on Tuesday, May 12th. Robert W. Baird set a $67.00 target price on shares of Haemonetics in a report on Friday, May 8th. Citigroup increased their target price on shares of Haemonetics from $64.00 to $70.00 and gave the company a “neutral” rating in a report on Thursday, May 28th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Haemonetics has an average rating of “Moderate Buy” and a consensus target price of $77.11.

Haemonetics Trading Up 2.1%

Shares of HAE opened at $71.31 on Friday. The stock has a market capitalization of $3.24 billion, a P/E ratio of 35.30, a PEG ratio of 1.43 and a beta of 0.56. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. The firm has a fifty day simple moving average of $60.00 and a two-hundred day simple moving average of $67.27. Haemonetics Corporation has a twelve month low of $47.31 and a twelve month high of $87.32.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.01. The business had revenue of $346.35 million during the quarter, compared to analysts’ expectations of $336.83 million. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The firm’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. On average, research analysts anticipate that Haemonetics Corporation will post 5.23 EPS for the current year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.